MER-104
MER-104 is in development for the treatment of Prostate Cancer.
MER-104 is a GnRH antagonist that takes advantage of GIPET technology and provides an oral dosage form alternative to current therapies, all of which are injectable. There are several GnRH antagonists either marketed or in development for the treatment of prostate cancer, endometriosis and benign prostatic hypertrophy (BPH). In general, these new compounds are less potent than the first generation agonists, and cause greater local tissue irritation when used in a long acting injection or subcutaneous implant delivery systems. The market adoption of the currently approved products has been low due to the fact that a small percentage of patients develop a severe allergic response to the large doses given by injection of subcutaneous depot. An oral product would eliminate the inconvenience of injection therapy, avoid the severe reactions, and allow tailored dosing regimens. Merrion has identified a potent GnRH antagonist with an attractive product profile for development as an oral dosage form for the treatment of prostate cancer as an initial indication. This compound is a novel chemical entity and has already been evaluated in Phase II clinical trials.
Clinical Data for MER-104 was presented at the AACR – NCI – EORTC International Conference on "Molecular Targets and Cancer Therapeutics" on the 24th Oct 2007 in San Francisco.
For more information or to view a copy of the poster, please click here.
